Funding for this research was provided by:
Received: 18 September 2020
Accepted: 21 October 2020
First Online: 17 November 2020
Ethics approval and consent to participate
: The trial was approved by the IRB of the University Dresden (DE/EKSN38, reference number: 26012014). After having signed informed consent, patients received a study smartphone (optional) and reimbursement of 35 € per month.
: The authors provide consent for publication.
: UE-P reports consultancy for Boehringer-Ingelheim. MB reports personal fees from Aristo Pharma GmbH, Hexal AG, Jannsen-Cilag GmbH, Neuraxpharm Arzneimittel GmbH, Novartis Pharma GmbH, Shire International GmbH, Sunovion Pharmaceuticals Inc., and Takeda Pharmaceutical Company. PR reports personal fees from Servier. ES reports personal fees from Aristo Pharma GmbH. The other authors declare no competing financial interests.